ArticleFrontiers in cellular and infection microbiology2014
Screening of Mycobacterium avium subsp. paratuberculosis mutants for attenuation in a bovine monocyte-derived macrophage model.
Article in Frontiers in cellular and infection microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Evaluation of the potential virulence of Mycobacterium avium subspecies paratuberculosis isolates from cattle in Uganda.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- The role of interleukin-10 receptor alpha (IL10Rα) in Mycobacterium avium subsp. paratuberculosis infection of a mammary epithelial cell line.BMC genomic data · 2024Article
- Modeling Paratuberculosis in Laboratory Animals, Cells, or Tissues: A Focus on Their Applications for Pathogenesis, Diagnosis, Vaccines, and Therapy Studies.Animals : an open access journal from MDPI · 2023Review
- Analysis of long non-coding RNA expression profile of bovine monocyte-macrophage infected by Mycobacterium avium subsp. paratuberculosis.BMC genomics · 2022Article
- Immunological Evaluation of Goats Immunized with a Commercial Vaccine against Johne's Disease.Vaccines · 2022Article
- Synthetic cathelicidin LL-37 reduces Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages.Cell and tissue research · 2020Article
- Mammalian cell entry operons; novel and major subset candidates for diagnostics with special reference toThe veterinary quarterly · 2019Review
- Vaccine approaches for the 'therapeutic management' ofThe veterinary quarterly · 2019Review
- Analysis of the microRNA Expression Profile of Bovine Monocyte-derived Macrophages Infected withInternational journal of molecular sciences · 2019Article
- A Rapid Method for Quantifying Viable Mycobacterium avium subsp. paratuberculosis in Cellular Infection Assays.Applied and environmental microbiology · 2016Article
- Development of vaccines to Mycobacterium avium subsp. paratuberculosis infection.Clinical and experimental vaccine research · 2016Review
- Controlling Johne's disease: vaccination is the way forward.Frontiers in cellular and infection microbiology · 2015Article
- A rational framework for evaluating the next generation of vaccines against Mycobacterium avium subspecies paratuberculosis.Frontiers in cellular and infection microbiology · 2014Review
- Generation and screening of a comprehensive Mycobacterium avium subsp. paratuberculosis transposon mutant bank.Frontiers in cellular and infection microbiology · 2014Article
- Evaluation of eight live attenuated vaccine candidates for protection against challenge with virulent Mycobacterium avium subspecies paratuberculosis in mice.Frontiers in cellular and infection microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination remains a major tool for prevention and progression of Johne's disease, a chronic enteritis of ruminants worldwide. Currently there is only one licensed vaccine within the United States and two vaccines licensed internationally against Johne's disease. All licensed vaccines reduce fecal shedding of Mycobacterium avium subsp. paratuberculosis (MAP) and delay disease progression. However, there are no available vaccines that prevent disease onset. A joint effort by the Johne's Disease Integrated Program (JDIP), a USDA-funded consortium, and USDA-APHIS/VS sought to identify transposon insertion mutant strains as vaccine candidates in part of a three phase study. The focus of the Phase I study was to evaluate MAP mutant attenuation in a well-defined in vitro bovine monocyte-derived macrophage (MDM) model. Attenuation was determined by colony forming unit (CFUs) counts and slope estimates. Based on CFU counts alone, the MDM model did not identify any mutant that significantly differed from the wild-type control, MAP K-10. Slope estimates using mixed models approach identified six mutants as being attenuated. These were enrolled in protection studies involving murine and baby goat vaccination-challenge models. MDM based approach identified trends in attenuation but this did not correlate with protection in a natural host model. These results suggest the need for alternative strategies for Johne's disease vaccine candidate screening and evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.